Correct Answer: D. Associated with sclerodactyly or Raynauds phenomenon
Scleredema (scleredema adultorum) is a benign, self-limited condition characterized by diffuse induration and thickening of the dermis, distinct from systemic sclerosis. The key discriminator is that scleredema does NOT associate with sclerodactyly or Raynaud's phenomenon—these are hallmark features of systemic sclerosis (scleroderma), not scleredema. Scleredema typically presents with sudden onset of firm, non-pitting edema and induration of the skin, often following a streptococcal infection (Group A Streptococcus) or in association with diabetes mellitus or thyroid disease. The dermis shows marked edema and fibrosis without the vascular changes, fibrointimal proliferation, or digital ulceration seen in systemic sclerosis. Histologically, the dermis becomes 3–4 times thicker than normal due to mucin deposition and collagen accumulation. The condition is benign and often resolves spontaneously over months to years. Sclerodactyly (tapering of fingers) and Raynaud's phenomenon are pathognomonic for systemic sclerosis and are NOT features of scleredema, making option D the false statement.
Why the other options are wrong
A. The dermis is 3-4 times thicker than normal — This is TRUE. Histopathology of scleredema shows marked dermal thickening (3–4 times normal) due to edema, mucin deposition, and collagen proliferation. This is a defining microscopic feature and is well-documented in dermatology textbooks. This is NOT the false statement. B. Can occur in association with diabetes — This is TRUE. Scleredema is classically associated with diabetes mellitus, particularly in poorly controlled cases. It is also seen post-streptococcal infection and with thyroid disease. The association with diabetes is well-established in Indian clinical practice and textbooks. This is NOT the false statement. C. Erythema and peau d'orange appearance of the skin can be seen — This is TRUE. Scleredema presents with erythema, edema, and a characteristic peau d'orange (orange-peel) appearance due to dermal thickening and involvement of hair follicles. These clinical signs are typical presentations. This is NOT the false statement.
High-Yield Facts
- Scleredema is a benign, self-limited dermal condition distinct from systemic sclerosis; it does NOT cause sclerodactyly or Raynaud's phenomenon.
- Dermis thickening in scleredema is 3–4 times normal due to mucin deposition and collagen, without vascular proliferation.
- Post-streptococcal infection (Group A Strep) is the most common trigger; also associated with diabetes and thyroid disease.
- Clinical presentation includes sudden onset of firm, non-pitting edema, erythema, and peau d'orange appearance on face, neck, and trunk.
- Histology shows dermal edema and fibrosis without the fibrointimal proliferation or digital ulceration of systemic sclerosis.
- Prognosis is excellent; condition is self-limited and often resolves spontaneously over months to years without treatment.
Mnemonics
Scleredema vs Systemic Sclerosis (Scleroderma) SCLEREDEMA: Self-limited, post-Strep, Skin only (no visceral), NO Sclerodactyly, NO Raynaud's. SYSTEMIC SCLEROSIS: Sclerodactyly, Sclerae (tight), Raynaud's, Renal crisis, Restrictive lung disease. Use: When differentiating benign dermal thickening from systemic disease. Scleredema Triggers (SAD) Streptococcal infection (post-strep), Associated with diabetes, Disease of thyroid. Use: To recall the three main associations of scleredema in clinical practice.
NBE Trap
NBE pairs scleredema with systemic sclerosis features (sclerodactyly, Raynaud's) to exploit students who confuse the two conditions. The trap is that both involve skin thickening, but only systemic sclerosis causes digital and vascular manifestations.
Clinical Pearl
In Indian clinical practice, scleredema is often seen post-streptococcal pharyngitis in children and young adults, and in poorly controlled diabetic patients. The key bedside pearl is that patients with scleredema have normal nailfolds and no digital ulcers—if you see these, think systemic sclerosis instead. Reassurance and glycemic control (if diabetic) are the mainstays of management.
_Reference: Robbins & Cotran Pathologic Basis of Disease, Ch. 25 (Skin); Harrison's Principles of Internal Medicine, Ch. 316 (Systemic Sclerosis and Related Disorders)_